SGLT2 inhibitors are the only existing therapy with proven benefit in HFpEF patients; a benefit that is due to lower HF hospitalisation rates, but with no significant reduction of cardiovascular mortality nor clinically meaningful improvements in quality-of-life scores [53, 51, 54]. The gene discussed is SLC5A2; the disease is hydrops fetalis.